Q2 Results Highlights: Mankind Pharma net profit rises 30% to Rs 653.5 crore

--Net profit rose 10% at Rs 2,690 crore versus Rs 2,442 crore

--Revenue at Rs 33,981 crore

--Revenue up 13.6% to Rs 3,076.51 crore versus Rs 2,708.10 crore

--Ebitda up 25% to Rs 850.04 crore versus Rs 682.65 crore.

--Margin at 27.6% versus 25.2%

--Revenue rose by 0.3% at Rs 2,774 crores versus Rs 2,767 crores

--EBITDA declines 8.3% at Rs 434 crore versus Rs 437 crore

--Net Profit down 7.6% at Rs 269 crore

--Net profit falls 25% at Rs 705 crore versus Rs 940 crore

--Total income rose 24% to Rs 12,458 crore versus Rs 10,027 crore

--Margin at 8.5% versus 11.3%

--Net profit falls 15% to Rs 1,255 crore

--Revenue rises 17% to Rs 8,106 crore

--Total income rises 21.3% at Rs 2,637 crore versus Rs 2,174 crore.

--Net Profit up 2% at Rs 572 crore versus Rs 561 crore.

--Revenue up 22% at Rs 2,633 crore versus Rs 2,161 crore

--Revenue up 16.8% at Rs 1,026 crore versus Rs 878 crore.

--Ebitda up 17.3% at Rs 828 crore versus Rs 706 crore.

--Margin at 80.7% versus 80.4%.

--Net profit up 0.1% at Rs 439.9 crore versus Rs 439.6 crore

Net Profit Up 23% at Rs 182 Cr Vs Rs 148 Cr (YoY)

Revenue Up 26.3% at Rs 421 Cr Vs Rs 334 Cr (YoY)

Net Profit Up 74.6% at Rs 47.5 Cr Vs Rs 27.2 Cr (YoY)

Revenue Up 18% at Rs 415 Cr Vs Rs 352 Cr (YoY)

EBITDA Up 52.2% at Rs 73.3 Cr Vs Rs 48.2 Cr (YoY)

--Margin at 17.6% Vs 13.7% (YoY)

Net profit up 76% at Rs 585 cr vs Rs 333 cr (YoY)

Revenue up 51% at Rs 2,757 cr vs Rs 1,828 cr (YoY)

EBITDA at Rs 510 cr vs Rs 176 cr (YoY)

Margin at 18.5% vs 9.6% (YoY)

Net profit flat at Rs 7 cr (YoY)

Revenue up 1.7% at Rs 291 cr vs Rs 286 cr (YoY)

EBITDA up 4.7% at Rs 17.8 cr vs Rs 17 cr (YoY)

Margin flat at 6% (YoY)

Board approves bonus issue of 1 share for every share held

Loss before exceptional items at Rs 5 cr vs profit of Rs 5.3 cr (YoY)

Revenue up 11% at Rs 162 cr vs Rs 145 cr (YoY)

Net Profit Down 6.2% at Rs 45 Cr Vs Rs 48 Cr (YoY)

Revenue Up 40.5% at Rs 242 Cr Vs Rs 172.3 Cr (YoY)

EBITDA Flat at Rs 61 Cr (YoY)

Margin At 25.2 % Vs 35.3% (YoY)

Analysts will closely monitor purchase trends in H2 of the current year, with more wedding dates and festivals to boost demand. Additionally, they will also pay attention to gold prices since gold prices have been recording fresh highs despite a cut in duty.

Indian-Made Foreign Liquor (IMFL) manufacturer Tilaknagar Industries Ltd on Monday reported a 57 percent rise in its consolidated net profit at Rs 58 crore crore in September 2024 quarter.

Share price surged 17 percent on November 5 on strong Q2 results.

More here.

Analysts at Motilal Oswal expect healthy growth in watches and other business while muted growth in eye care segment.

However, Kotak Institutional Equities sees 15 percent growth in watches division and 10 percent growth in eyewear.

Titan’s jewellery business delivered strong recovery after a muted Q1 aided by reduction in custom duty on gold imports in July 2024.

According to Kotak Institutional Equities, Titan will see 21 percent on-year standalone recurring jewelry sales growth, with demand boosted by custom duty cut.

Brokerages are estimating that Titan Company will record a one-time inventory loss at around Rs 300-325 crore.

This assumes about ~70 percent of overall impact pertaining to custom duty cut in 2Q. However, they have not included this in their expectations, as it would be likely classified as an exceptional item.

According to a Moneycontrol poll of six brokerages, the jewellery major is likely to report a 14.4 percent revenue growth at Rs 13,478 crore. Net profit is likely to come in at Rs 1,028 crore, jumping 9 percent from Rs 940 crore in the corresponding quarter last year.

GAIL India, Titan, SVJN, Max Healthcare among companies to report Q2FY25 earnings today

Dr Reddy's Laboratories, Berger Paints India, JK Tyre & Industries, Manappuram Finance among others, also will also announce their July-September quarter results on today.